Syngene reported healthy 24% YOY growth in EBITDA at Rs.225 crore for the fourth quarter ended March 2020. EBITIDA margins were higher by 300 basis points to 36% in the fourth quarter. Overall, in revenue terms, Syngene reported 13% growth at Rs.628 crore on a YOY basis. Syngene is a unit of Biocon of Bengaluru and had have been hived off as a separate company just a few years back. Net profits of the company were also up by 20% at Rs.120 crore. The big trigger for the growth was the strong growth in its discovery and development services divisions. It also commissioned a new research facility at Biocon Park in Bengaluru. Syngene also cleared US FDA inspection of its small molecule bio-analytical laboratory within the clinical development unit. The stock was up by nearly 5% at Rs.342 and investors are seeing this as a de-risked pharma bet in these volatile times.